Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
WO2020180770A1
Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1
Bicyclic heteroaryl compounds and uses thereof
AR115671A1
MACROCYCLIC COMPOUNDS AS COVALENT DRUGS LINKED TO RAS PROTEIN AND THEIR USE FOR THE TREATMENT OF CANCER
WO2020132597A1
Compounds that participate in cooperative binding and uses thereof
WO2020076723A1
Shp2 inhibitor compositions for use in treating cancer
EP3788050A1
C26-linked rapamycin analogs as mtor inhibitors
KR20210018244A
C40-, C28- and C-32-linked rapamycin analogs as mTOR inhibitors
EP3773590A1
Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
CA3084058A1
Polycyclic compounds as allosteric shp2 inhibitors
WO2019075265A1
Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
KR20200051684A
SHP2 inhibitor compositions and methods for the treatment of cancer
SG11201909924VA
Rapamycin analogs as mtor inhibitors
EP3606492A1
Compounds that participate in cooperative binding and uses thereof
SG11201906412SA
Pyridine compounds as allosteric shp2 inhibitors
EP3571199A1
Bicyclic compounds as allosteric shp2 inhibitors
TW201808931A
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
